New Heart Program Saves Patients For Fertility Medications
Ferring Pharmaceuticals announced a new, improved cost-saving program for heart patients who are considering fertility treatment, but find the costs a challenge.
Ferring's HEART (Helping Expand Access to Reproductive Therapy) Program gives women greater access to fertility medications, saving them as much as $700 on two frequently prescribed fertility treatments. The expanded program now includes both BRAVELLE (urofollitropin for injection, purified) and ENDOMETRIN (progesterone) Vaginal Insert, 100 mg, a new Ferring product for progesterone supplementation, administered following treatment with BRAVELLE.
"In our ongoing effort to increase access to safe, effective fertility treatments, we have expanded our long-time HEART Program to give qualified couples a greater chance to build families," said Olivier Delannoy, Vice President, Infertility, at Ferring. "We believe that cost should not be a barrier to parenthood."
With Ferring's expanded HEART Program, patients can receive up to 10 vials of BRAVELLE free of charge as part of their prescription (for a minimum of 40 vials) and one free box (21 vaginal inserts) of ENDOMETRIN.